TY - JOUR JO - EuroIntervention TI - Clinical outcomes of bioabsorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: two-year follow-up of the DESSOLVE III trial AB - <p><strong>Aims:</strong> The aim of this study was to assess whether the nine months of cytostatic inhibition by crystalline sirolimus has a beneficial effect in the two-year follow-up in an all-comer population undergoing percutaneous coronary intervention.</p> <p><strong>Methods and results:</strong> The DESSOLVE III study (n=1,398) is a prospective, all-comer, multicentre, randomised controlled study (NCT02385279) allocating 703 patients to receive the MiStent drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall, and 695 patients to receive the XIENCE durable polymer everolimus-eluting stent. At two years, the device-oriented composite endpoint (cardiac death, target vessel myocardial infarction [TV-MI], and clinically indicated target lesion revascularisation [TLR]) occurred in 8.7% and 8.6% (p=0.958) of patients, and the patient-oriented composite endpoint (all deaths, all MI, and all revascularisations) was observed in 18.5% and 19.6% (p=0.598) of patients in the MiStent and XIENCE arms, respectively. The frequency of TV-MI and clinically indicated TLR was also comparable for both stent types. The rate of definite/probable stent thrombosis was not different in the two arms (0.9% vs 1.3%, p=0.435).</p> <p><strong>Conclusions:</strong> In an all-comer population, at two-year follow-up, the use of the MiStent sirolimus-eluting bioabsorbable polymer-coated stent was at least as safe and efficacious as the XIENCE durable polymer stent. The MiStent&rsquo;s potential long-term clinical benefit will be further elucidated after five years of follow-up.</p> AU - Katagiri Yuki AU - Onuma Yoshinobu AU - Lurz Philipp AU - Buszman E. Pawel AU - Piek J. Jan AU - Wykrzykowska Joanna J. AU - Asano Taku AU - Kogame Norihiro AU - Takahashi Kuniaki AU - Chang Chin Chun AU - de Winter J. Robbert AU - Serruys Patrick W. AU - Wijns William VL - 15 IS - 15 Y1 - 07/02/2020 Y1 - 2020 DOI - 10.4244/EIJ-D-18-00944 SP - e1366 EP - e1374 KW - drug-eluting stent KW - clinical trials KW - stable angina KW - acs/nste-acs PB - Europa Digital & Publishing SE - Coronary interventions UR - https://eurointervention.pcronline.com/article/two-year-follow-up-of-the-dessolve-iii-trial-bioabsorbable-polymer-sirolimus-eluting-stent-vs-durable-polymer-everolimus-eluting-stent SN - 1774-024X ER -